Idelalisib

Contraindicated

Idelalisib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Idelalisib Simvastatin Flolipid Explained Increased simvastatin concentrations and risk of myopathy and rhabdomyolysis Details Idelalisib Alfuzosin UroXatral Increased alfuzosin exposure and risk for toxicity Details Idelalisib Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of acute ergot toxicity Details Idelalisib Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of acute ergot toxicity Details Idelalisib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Idelalisib Ivabradine Corlanor Increased ivabradine exposure and an increased risk of ivabradine-related adverse effects [like bradycardia and conduction disturb... Details Idelalisib Lovastatin Altocor® Increased lovastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Idelalisib Lurasidone Latuda Increased lurasidone exposure Details Idelalisib Naloxegol Movantik Increased naloxegol exposure and an increased risk of naloxegol-related adverse effects Details

Major

Idelalisib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Idelalisib Abametapir Explained Increased exposure of CYP3A4 substrate Details Idelalisib Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Idelalisib Acalabrutinib Calquence Increased acalabrutinib exposure Details Idelalisib Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Idelalisib Apixaban Eliquis Explained Increased apixaban exposure Details Idelalisib Aripiprazole Injection Abilify Increased ARIPiprazole exposure Details Idelalisib Asciminib Scemblix Increased asciminib exposure and an increased risk of asciminib-related adverse effects Details Idelalisib Atogepant Qulipta Increased atogepant exposure Details Idelalisib Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Idelalisib Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Idelalisib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Idelalisib Avanafil Stendra Decreased avanafil clearance and increased avanafil plasma concentration Details Idelalisib Beclomethasone Nasal Spray Beconase Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Idelalisib Beclomethasone Oral Inhalation Beclovent® Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Idelalisib Bedaquiline Sirturo Increased bedaquiline exposure Details Idelalisib Bosutinib Bosulif Increased bosutinib exposure Details Idelalisib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Idelalisib Brigatinib Alunbrig Increased brigatinib exposure Details Idelalisib Budesonide Entocort Increased exposure of CYP3A substrate Details Idelalisib Budesonide Nasal Spray Rhinocort Increased exposure of CYP3A substrate Details Idelalisib Budesonide Oral Inhalation Pulmicort Increased exposure of CYP3A substrate Details Idelalisib Cabazitaxel Injection Jevtana Increased cabazitaxel exposure Details Idelalisib Cabozantinib Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Idelalisib Cabozantinib (Thyroid Cancer) Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Idelalisib Calcifediol Rayaldee Altered serum levels of calcifediol Details Idelalisib Cobimetinib Cotellic Increased cobimetinib exposure Details Idelalisib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Idelalisib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Idelalisib Dasatinib Phyrago Increased dasatinib exposure and an increased risk of dasatinib-related adverse effects Details